Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq
@ASCO
Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance
https://t.co/kXkfPZwg0J
😃Honored to share our new collaborative study published in the Journal of Nephrology! 🎓💻
“Comparison of human vs AI-generated feedback: results from an online survey study in the GlomCon glomerular disease fellowship program.”
🔗 Read the full article here: https://t.co/oEkL2xEhNn
What happens when we directly compare AI-generated educational feedback to human-generated feedback in advanced medical training? In this study, we explored how learners perceived both approaches across several critical domains.
💡 Key Findings:
We discovered that AI-generated feedback performed comparably to human-generated feedback across multiple learner-centered outcomes, including:
🔹 Fairness
🔹 Constructiveness
🔹 Supportiveness
🔹 Utility for Improvement
The Big Picture: As generative AI continues to rapidly evolve within nephrology and academic medicine, its role is not to replace human mentorship, but to augment it. Thoughtful evaluation of how AI can enhance education and deliver structured, timely feedback will become increasingly vital in fellowship training.
😃 I am incredibly grateful to collaborate with such an outstanding team at the intersection of nephrology, education, and responsible AI implementation: Niloufar Ebrahimi , Zohreh Gholizadeh Ghozloujeh, Lawrence K. Loo, Pravir Baxi, Zhabiz Solhjou, Arun Rajasekaran, Zainab Obaidi, Arvind Singh, Rica Mae Pitogo, and Sayna Norouzi MD . 🤝✨@n0r0zha@SaynaNorouzi@MayoClinicNeph
🔗 Read the full article here: https://t.co/oEkL2xEhNn
Wisit Cheungpasitporn, MD, FACP, FASN, FAST
Professor of Medicine & Clinician-Scientist, Mayo Clinic
Leading AI Innovation in Kidney Care & Medical Education
#AIinMedicine #MedicalEducation #Nephrology #ArtificialIntelligence #GenerativeAI #GlomCon #DigitalHealth #KidneyEducation #MedEd #KidneyCare #FutureOfMedicine
Which one is more likely to represent MGRS pspectrum ?
1. Monotypic DNAJB9 positive Fibrillary GN
2. Membranous-like glomerulopathy with Masked IgGK deposits
3. PGNMID IgG3 variants
4. Light chain cast nephropathy
5. Non-hepatitis Seronegative Type 2 Cryoglobulinemic GN
😊🙏🏻Excited to share our new publication in American Journal of Kidney Diseases:
@AJKDonline
“Deceased Donor Kidney Transplantation Versus Continued Dialysis Among Patients Aged 75 Years or Older: A Target Trial Emulation.”
https://t.co/ZzSVe1eO6T
This study addresses a clinically important and increasingly common question in nephrology and transplant medicine:
Should carefully selected adults ≥75 years old remain on dialysis or pursue deceased donor kidney transplantation?
Using a target trial emulation framework with sequential trials methodology, we analyzed outcomes among transplant-eligible older adults listed in the OPTN registry from 2015–2023.
Key findings:
* Kidney transplantation in adults ≥75 years was associated with an early postoperative mortality risk during the first 90 days.
* Survival benefit emerged gradually over time, with a break-even point around 3 years.
* By 5 years, deceased donor kidney transplantation conferred an approximately 111-day survival advantage compared with remaining on dialysis.
* Findings support individualized decision-making rather than a one-size-fits-all approach for older transplant candidates.
Importantly, the study highlights that dialysis may remain a reasonable alternative for some older adults, particularly when considering frailty, symptom burden, quality of life, and competing risks.
Congratulations to all co-authors and collaborators on this important work in advancing evidence-based care for older adults with kidney failure.
Authors: Napat Leeaphorn, Rose Mary Attieh, Katherine M. Oshel, Oscar A. Garcia Valencia, Wisit Cheungpasitporn, Tambi Jarmi, and colleagues.
@napatlee1@OscarGarciaMD@MayoClinicNeph
📍
National Kidney Foundation @nkf
#Nephrology #KidneyTransplant #Transplantation #Dialysis #KidneyDisease #AJKD #TargetTrialEmulation #ClinicalResearch #ESKD #KidneyCare
Approach to Non-Albumin predominant proteinuria .
Suspect when
- There is discrepancy between dipstick and 24hr proteinuria or
- UACR not making predominant part of UPCR .
Which is a better treatment for people with hyperkalemia: sodium zirconium cyclosilicate (SZC) or patiromer? That depends. Find out why in the #ASNKidney360 study. https://t.co/RYsFq2uuZD
Today we’re introducing two big steps for health at OpenAI:
- ChatGPT for Clinicians, a free version of ChatGPT designed for clinical work
- HealthBench Professional, a new benchmark to evaluate real clinician chat tasks
We’re excited about what this can unlock for care. ❤️